Logo_AIHTA
  • English
            Menu_button
                                Video
                                Video: What is HTA?    
                                • Home
                                • News

                                News

                                Leiste32


                                Welcome to the homepage of AIHTA!

                                AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.

                                In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.

                                Subscribe to newsletter

                                2192
                                ©stock.adobe.com

                                Announcement

                                Horizon Scanning in Oncology - Fact Sheets

                                We are pleased to introduce you three new Fact Sheets.

                                Fact Sheet No. 177 (May 2024)
                                Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first?line treatment of metastatic non-small-cell lung cancer (NSCLC)

                                Fact Sheet No. 178 (May 2024)
                                Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC) 

                                Fact Sheet No. 179 (May 2024)
                                Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) 

                                More...

                                Newsletter_preview

                                Newsletter

                                Inhalt

                                • Editorial: Neue Methoden aus der Gesundheitsökonomie machen Auswirkungen neuer Leistungen auf gesundheitliche Ungleichheit sichtbar
                                • Pharmakogenetik: personalisierte Verschreibungen
                                • Hautkrebsprävention: Leitlinien-Empfehlungen zur Primär- und Sekundärprävention
                                • Gentests bei familiärer Hypercholesterinämie
                                • Fernüberwachung bei chronischen körperlichen Erkrankungen
                                • Termine
                                • Themen-Vorschau
                                Print Zur Druckversion...
                                2191
                                ©stock.adobe.com

                                Announcement

                                Horizon Scanning in Oncology - Fact Sheets

                                We are pleased to introduce you six new Fact Sheets.

                                Fact Sheet No. 171 (April 2024)
                                Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC)

                                Fact Sheet No. 172 (April 2024)
                                Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2 negative locally advanced or metastatic breast cancer

                                Fact Sheet No. 173 (April 2024)
                                Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK positive non-small cell lung cancer (NSCLC)

                                Fact Sheet No. 174 (April 2024)
                                Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma

                                Fact Sheet No. 175 (April 2024)
                                Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion

                                Fact Sheet No. 176 (April 2024)
                                Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations

                                More...

                                Newsletter_preview

                                Newsletter

                                Inhalt

                                • Editorial: AIHTA-Framework erleichtert Identifikation öffentlicher Beiträge zur Entwicklung von Innovationen im Gesundheitswesen
                                • Biofeedback-Therapie bei Migräne
                                • Preis- und Kostenentwicklung von Orphan Drugs
                                • Modelle der primären Gesundheitsversorgung für Obdachlose
                                • CAR-basierte Immuntherapie mit Fokus auf CAR-NK-Zellen
                                • Termine
                                • Themen-Vorschau
                                Print Zur Druckversion...
                                Bild-weight-stigma-ki-generiert
                                AI generated

                                Project / ,

                                Strategies to reduce weight stigmatisation of people with overweight or obesity in the healthcare sector

                                Project leaders: /page/sarah-wolf/en

                                Project team: /page/sarah-wolf/en, /page/julia-kern/en

                                Duration: Mid-April 2024 until Mid-November 2024
                                Language: German (with English executive summary)
                                Publication: HTA Project Report No. 160: https://eprints.aihta.at/1547/

                                More...

                                2189
                                ©stock.adobe.com

                                Announcement

                                Horizon Scanning in Oncology - Fact Sheets

                                We are pleased to introduce you three new Fact Sheets.

                                Fact Sheet No. 168 (March 2024)
                                Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas

                                Fact Sheet No. 169 (March 2024)
                                Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours

                                Fact Sheet No. 170 (March 2024)
                                Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC)

                                More...

                                Newsletter_preview

                                Newsletter

                                Inhalt

                                • Editorial: „Unmet Need“ (ungedeckte Bedarfe): Eine Definition steht noch aus
                                • Wundversorgung: Integrierte digitale Wundpflegesysteme
                                • Implantierte Sensoren: Messung und Monitoring des pulmonal-arteriellen Drucks bei Herzinsuffizienz
                                • Finanzielle Anreize in der integrierten Versorgung
                                • Künstliche Intelligenz: Erkennung und Charakterisierung von Darmkrebsvorstufen bei der Darmspiegelung
                                • Termine
                                • Themen-Vorschau
                                Print Zur Druckversion...
                                2188
                                ©stock.adobe.com

                                Announcement

                                Horizon Scanning in Oncology - Fact Sheets

                                We are pleased to introduce you four new Fact Sheets.

                                Fact Sheet No. 164 (February 2024)
                                Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

                                Fact Sheet No. 165 (February 2024)
                                Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma

                                Fact Sheet No. 166 (February 2024)
                                Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM)

                                Fact Sheet No. 167 (February 2024)
                                Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC)

                                More...

                                Newsletter_preview

                                Newsletter

                                Inhalt

                                • Editorial: Zugang zu Medikamenten in Österreich: Warum Geschwindigkeit nicht alles ist
                                • Autologe Fetttransplantation bei Arthrose
                                • Telepathologie bei der intraoperativen Schnellschnittuntersuchung
                                • Liposuktion zur Entfernung subkutaner (großer) Lipome
                                • Calcitonin-Gene-Related-Peptide (CGRP)-Antagonisten zur Migräneprävention
                                • Termine
                                • Themen-Vorschau
                                Print Zur Druckversion...
                                Newsletter_preview

                                Newsletter

                                Inhalt

                                • Editorial: Advanced Practice Nursing (APN): Kompetenz, Leadership, Karriere
                                • Unterstützung rationaler Impfpolitik
                                • Implementierung der „Krankenhausausnahmegenehmigung“ für ATMPs in sechs ausgewählten EU-Ländern
                                • Telemedizin und Künstliche Intelligenz im intramuralen Bereich Österreichs
                                • Cranberries (Vaccinium macrocarpon) zur Prävention von Harnwegsinfekten
                                • Termine
                                • Themen-Vorschau
                                Print Zur Druckversion...
                                « < ... 3 4 5 6 7 ... > »
                                Displaying results 41 to 50.
                                                                                                  Netzwerk
                                                                                                  • Ebm
                                                                                                  • Inahta
                                                                                                  Shareholder
                                                                                                  • Bmfg
                                                                                                  • Sv
                                                                                                  • Wgfond
                                                                                                  • Noe
                                                                                                  • Ooghfond
                                                                                                  • Ghls
                                                                                                  • Tirol
                                                                                                  • Vorarlberg
                                                                                                  • Kghfond
                                                                                                  • Ghpf
                                                                                                  • Burgef
                                                                                                            © 2025 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                            • Log in